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Abstract
In this paper we report on the development and validation of two different methods for posaconazole quantification from serum sam-
ples, HPLC/UV and bioassay. Both methods have been validated according to international guidelines and were also applied to the analy-
sis of 61 trough serum samples from treated patients. A good correlation between both methods was observed. The HPLC method,
more laborious and expensive, was demonstrated to be more accurate, precise and faster (analytical range 0.125–16 lg/mL, accuracy
between )2.48 and 3.70% and precision between 2.77 and 5.93%, with an analytical run time of 11 min), making it a valuable tool for
reference laboratories that centralize high numbers of samples. The microbiological method, however, is simple and offers sufficient
precision and accuracy (analytical range 0.125–16 lg/mL, accuracy between )8.10 and 3.77% and a precision between 4.52 and 10.07%),
to be used to monitor posaconazole. It may be a valid alternative to chromatographic methods in clinical laboratories without special-
ized facilities.
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Introduction
Posaconazole is a new triazole with broad-spectrum antifun-
gal activity against Candida, Aspergillus and Fusarium species,
as well as against zygomycetes [1]. It has proven effective as
a curative treatment of invasive fungal infections, mostly inva-
sive aspergillosis and refractory mucosal candidiasis, and for
antifungal prophylaxis in patients with graft-versus-host dis-
ease, as well as in patients with prolonged neutropenia in
acute leukaemia [2–5]. Posaconazole is a highly lipophylic
weak base structurally related to itraconazole. It belongs to
class II compounds, indicating that it is well absorbed but dis-
solves slowly in water (high permeability/low solubility) [6].
Similar to other triazoles, marked interpatient variability
(between-patient variability in blood concentration after
receiving the same dose), for both healthy volunteers and
patient populations has been described. Several factors can
impact posaconazole disposition: first, the only available for-
mulation is an oral suspension that shows a great variability
of absorption. Prandial state and meal composition (specifi-
cally fat), gastric pH or mucosal integrity impact significantly
on posaconazole absorption [7]. Moreover, dose frequency
has been proven to influence posaconazole disposition [8].
With regard to the pharmacodynamic endpoints associated
with optimal treatment, certain evidence has suggested a
relationship between exposure and efficacy for this com-
pound [9]. Hence, the concept of posaconazole therapeutic
drug monitoring should be explored at length in future clini-
cal studies.
To perform therapeutic drug monitoring, several quantifi-
cation methods of posaconazole in serum by HPLC and by
liquid chromatography–tandem mass spectrometry methods
have been described in the literature [10–14]. As far as we
know, only one microbiological method (bioassay) has been
described for posaconazole monitoring [15]. It offers several
practical advantages, such as simplicity and low costs, and is
therefore a valid alternative to chromatographic methods in
clinical laboratories without specialized equipment.
We aim to report on the development and validation of a
rapid HPLC/UV for posaconazole detection method with
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ravuconazole as the extraction standard (ES) from human
serum. The chromatographic method was validated according
to international guidelines in terms of stability, specificity, lin-
earity, precision and accuracy for serum matrix [16,17].
Additionally a bioassay for posaconazole quantification was
also described and validated. Our experience with both ana-
lytical methods to measure serum concentrations of posaco-
nazole in patients under treatment or receiving prophylaxis
is reported.
Materials and Methods
Chemicals, instruments and chromatographic conditions
Stock solutions of posaconazole (Merck & Co., Inc., Rahway,
NJ, USA) and the ES, ravuconazole (Brystol Myers Squibb
Company, Madrid, Spain) were prepared on dimethyl sulfox-
ide (DMSO; Sigma-Aldrich, Madrid, Spain) from authenticated
analytical reference powder. Human commercial serum from
human male AB Plasma, supplied by Sigma-Aldrich, was used
as a matrix for solution preparation. Other antifungal drugs
used were Amphotericin B (Sigma-Aldrich), flucytosine
(Sigma-Aldrich), fluconazole, (Pfizer S.A., Madrid, Spain),
itraconazole (Sigma-Aldrich), hydroxy-itraconazole (Janssen
Pharmaceutica, Madrid, Spain), voriconazole (Pfizer S.A.),
caspofungin (Merck & Co., Inc.), micafungin (Astellas Pharma,
Inc., Tokyo, Japan) and anidulafungin (Pfizer S.A).
Chromatographic and detection conditions are described
in Table 1. The mobile phase consisted of a filtered and
degassed mix of acetonitrile : ultrapure water (60 : 40, v/v).
Preparation of solutions
Two separate stock solutions of posaconazole were prepared
for calibration standards (CS) and quality controls (QC),
respectively, by dissolving 3.2 mg posaconazole in 2 mL
DMSO for each solution yielding concentrations of 1.6 mg/mL.
One solution was used to prepare eight CS at final con-
centrations of 0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 lg/mL by
spiking adequate amounts of the posaconazole stock solution
into drug-free human serum. In the same manner, an addi-
tional five QC samples were prepared using the second
stock solution of posaconazole to obtain final concentrations
0.25, 0.5, 1, 4 and 8 lg/mL. A standard stock solution of ES
was prepared at 200 lg/mL in DMSO. For the bioassay pro-
cedure, ES was not added when QC or CS solutions were
prepared.
Chromatographic assay
The CS and QC sample solutions were processed as follows:
Ice-cold acetonitrile in a volume of 150 lL was added in
1 : 1 proportion. This solution also included a volume of ES
to result in a final concentration of 2 lg/mL. The resulting
mixture was then shaken for 30 s on a Vortex Shaker at
maximum speed followed by centrifugation at 13 800 g at
25C for 15 min. Fifty microlitres of the supernatant was
then injected into the chromatographic system and analysed.
Bioassay
The biological activity of posaconazole in serum samples was
also measured by a diffusion assay. One hundred and fifty mil-
lilitres of medium containing 6.7 g/L yeast nitrogen base
(YNB, Difco Becton Dickinson), 10 g/L glucose (Sigma-
Aldrich, Madrid, Spain), 5.9 g/L trisodium citrate and 14 g/L
agar were prepared aseptically in two volumes (15 mL of fil-
tered broth medium and 135 mL of autoclaved agar solution).
A susceptible strain of Candida kefyr (ATCC 28838, posaco-
nazole MIC 0.015 lg/mL) was used as a test organism. For
the assay, 1–5 CFU of the subcultured yeast were tipped and
suspended in 3.0 mL sterile water. The turbidity of the sus-
pension was adjusted to a McFarland standard of 0.5 (530 nm,
1· 106 to 5 · 106 CFU/mL). One hundred and thirty-five milli-
litres of agar solution, 15 mL broth medium and 1.5 mL inocu-
lum (final ionoculum size 104 CFU/mL) were then mixed at a
temperature of 50C, poured into 250 · 250-mm square
plates (NIRCO Diagno´stico e Investigacio´n, Madrid, Spain) and
allowed to solidify on a level surface at room temperature for
45–60 min. Thereafter, 37-mm diameter wells were bored
aseptically with the help of a sterile cork borer in a well-spaced
pattern. Fifty microlitres of each standard, control or sample
were pipetted in triplicate into individual wells of the plate. No
protein precipitation pre-treatment was performed. The plates
were incubated for 24 h at 37C.
The assay was repeated over 4 days for QC, 2 days for CS
and once for clinical samples. Zones of inhibition were mea-
sured to the nearest 0.1 mm using a metric calliper microme-
ter (Fowler, Ultra-cal II. Sylvac, Be´vilard, Switzerland).
TABLE 1. Chromatographic and instrumental conditions
Instrumental parameters Conditions
Elution mode Isocratic (60 : 40 acetonitrile:water)
Flow rate 0.8 mL/min
Volume of injection 50 lL
Wave length detection 262 nm
Column Sunfire C18 5 lm 4.6 · 150 mm
Guard column Sunfire C18 5 lm 4.6 · 20 mm
Temperature of the column 25C
Temperature of the auto sampler 25C
Pressure of the system 1200–1500 Psi
Quantitative detection methodology Peak area
Qualitative detection methodology Time retention; UV Spectrum
Calibration mode Calibration curve
Concentration units lg/mL
Analytes time retention Posaconazole 6.50 ± 0.1 min
Ravuconazole 9.95 ± 0.1min
Run time 11 min
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Validation procedures
HPLC assay. The HPLC method was assayed for linearity,
precision and accuracy, recovery rate, selectivity and stability.
Linearity was assessed by linear regression (best fit obtained
when plotting peak areas measured by HPLC against posaco-
nazole concentration in the range of 0.125–16.0 lg/mL).
Experiments were performed in quadruplicate on two non-
consecutive days. In addition, intra-day and inter-day preci-
sion and accuracy (expressed as coefficient of variation
(CV%) and relative error (RE%), respectively) were evaluated
by triplicate processing and analysis of five QC samples
(0.25, 0.5, 1, 4 and 8 lg/mL) on five non-consecutive days.
Criteria for acceptability of data included accuracy (RE%)
within ±15% deviation from the nominal values and precision
within ±15% of CV%, except for the lower limit of quantifi-
cation (LLOQ), for which data should not exceed 20% of
CV% [16,17].
Recovery experiments (extraction efficiency) were per-
formed by comparing results of extracted samples (0.5, 2
and 4 lg/mL, n = 3) with the unextracted standards that rep-
resent 100% recovery.
Selectivity was investigated for potential interference by
endogenous substances by using six independent batches of
human serum samples. Selectivity was indicated by the
absence of any endogenous interference peaks at posaconaz-
ole and ES retention times.
The specificity was evaluated with respect to all the regis-
tered antifungal agents listed above and some antibacterial
drugs (amoxicillin/clavulanic acid, imipenem, ciprofloxacin,
gentamicin and ceftazidime) commonly used in patients trea-
ted with posaconazole. Specificity was indicated by the
absence of interference peaks at the same retention times of
posaconazole.
Quality controls were also tested for stability of posaco-
nazole under a variety of storage and handling conditions: (i)
three freeze–thaw cycles (three freeze ()20C)–thaw (room
temperature) cycles), (ii) short-term storage (freeze for 24 h
at )20C and then thaw for 4 h at room temperature), (iii)
long-term storage (freeze for 1 month at )20C and then
thaw for 4 h at room temperature), (iv) bench-top stability
(storage at room temperature for 24 h and 90 h, and then
processed), and (v) stock solution stability (evaluation of
stock solution in DMSO tested at the beginning of the
experiments and then after being stored at )20C for
2 months, which is the estimated time for this validation pro-
cedure). All stability tests in serum matrix were performed
using low (0.5 lg/mL), medium (2 lg/mL) and high (4.0 lg/
mL) QC concentrations, and analysed in triplicate. Addition-
ally, our laboratory participates in the international quality
control programme of antifungal drugs of the Association for
Quality Assessment in Therapeutic Drug Monitoring and
Clinical Toxicology (KKGT) [18].
Bioassay. The bioassay was also tested for linearity, precision
and accuracy. Different experiments that included eight CS,
five QC, both in triplicate, and a blank matrix control were
performed for the procedure validation.
Intra-day and inter-day precision and accuracy of the analyt-
ical method were evaluated by triplicate processing and analy-
sis of five QC samples (0.25, 0.5, 1, 4 and 8 lg/mL), on three
non-consecutive days. Criteria for acceptability of data were
the same as previously described for HPLC methodology.
Measurements of posaconazole in clinical samples
Sixty-one serum samples from patients who received posaco-
nazole oral suspension for different indications were evalu-
ated. A sample volume of 300 lL was used for sample
preparation and concentration measurement, 150 lL was
used for HPLC evaluation and the remaining 150 lL for the
microbiological method.
Clinical samples were processed as described above for
each methodology. Hospital patients signed the informed
consent form, which authorized researchers to perform
therapeutic drug monitoring of posaconazole and analysis
thereof.
Concordance between HPLC and bioassay
The agreement between posaconazole levels measured by
HPLC and bioassay was evaluated by using the intra-class
correlation coefficient (ICC, PASW STATISTICS 18, PAWS Sta-
tistics, Madrid, Spain), which was expressed to a maximum
value of 1 and with a 95% CI. The ICC is a reverse measure-
ment of the variability of the counting values. It can reach a
maximum value of 1 if there is a perfect correlation and a
minimum value of )1 if there is a complete absence of cor-
relation. The ICC is a scale analysis and provides the highest
statistical power for correlation studies. A p value of <0.01
was considered to be statistically significant.
Results were also compared by the least-squares linear
regression using standard techniques (EVIEWS statistics pro-
gram, Quantitative Micro Software). For these calculations,
HPLC was considered the reference method.
Results
High performance liquid chromatography
Posaconazole was correctly separated and detected following
the chromatographic conditions described above, posaconaz-
ole eluted at 6.50 ± 0.2 min and ES at 9.95 ± 0.2 min. A linear
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relationship (y (peak area) = 79174x (posaconazole concen-
tration)) was found over a range of drug concentrations
tested (r2 = 0.9994). The LLOQ of posaconazole was deter-
mined to be 0.125 lg/mL. The limit of detection was found
to be 0.06 lg/mL. The within-days and between-days preci-
sion for QC samples was <15%. The method also showed an
accuracy within 15% (20% for LLOQ), as is described in
Table 2. Absence of carryover was detected after injection
of the highest QC samples (16 lg/mL). In conclusion, CV%
and RE% data obtained for posaconazole were within accept-
able limits stated for bioanalytical method validation by the
Food and Drug Administration and European Medicines
Agency [16,17].
The mean recovery from human serum was in the range
91.63–104.69% for posaconazole. The mean recovery of the
ES was 102.11%. Posaconazole-free serum samples did not
show any interference with posaconazole signal. Interactions
between most antifungal and antibacterial drugs tested,
matrix components and posaconazole were not observed. It
is worth noting that hydroxy-itraconazole showed a reten-
tion time close to that of posaconazole (6.30 ± 0.1 min vs.
6.50 ± 0.2 min).
Results of stability conditions are listed in Table 3. Data
show that posaconazole was stable under most of the condi-
tions tested. The only factor slightly affecting posaconazole
quantification was the storage of samples at room tempera-
ture (between 20.5 and 36.2% disagreement between peak
areas). For this reason, the freezing of serum samples or
processing them within 24 h of receipt is recommended.
Quality control programme results
Regarding results from the 2010 quality control programme
for posaconazole, three out of four (75%) samples analysed
passed the requirements defined by the programme regula-
tions. These results were inside the 80–120% acceptable
range for the theoretical value (median 95%, range 90–
100%), providing an additional external validation of the
method.
Bioassay
Standard curve was logarithmic in the range of 0.125–16 lg/mL
(Fig. 1). The LLOQ and limit of detection were 0.125 lg/mL.
Inter-day and intra-day values for accuracy and precision were
below )8.10, 10.07% and 7.88, 5.47% respectively (Table 2).
Concordance between HPLC and bioassay results
Results from clinical samples ranged from 0.00 to 1.517 lg/
mL by bioassay and from 0.00 to 1.916 lg/mL using HPLC
methodology. Data below LLOQ were coded as 0.00 lg/mL.
Overall, the correlation between results was good with an
ICC value of 0.915 (0.86–0.95, p <0.01). Results of linear
regression analysis were also acceptable as described below:
Bioassay = 0.742(HPLC) + 0.026; R2 = 0.871, with a coeffi-
cient of correlation = 0.931; n = 61 runs (Fig. 2).
Discussion
We describe and compare two different methodologies,
HPLC and a bioassay, for posaconazole quantification from
clinical samples. Both methods offer interesting advantages.
HPLC has been described as a more accurate, precise and fas-
ter methodology, being a useful tool for therapeutic drug
monitoring and pharmacokinetic studies [19]. We found in
our study that the HPLC method offers superior precision
and accuracy compared with the microbiological method
(Table 2). Additional advantages such as a simple sample pre-
treatment procedure (single-step protein precipitation with
acetonitrile [13]), the use of ravuconazole as ES (with similar
chemical profile to ensure a comparable chromatographic
TABLE 2. Within-day and between-day precision (calculated as coefficient of variation, CV) and accuracy (expressed as per -
cent of the relative error, RE) for HPLC and bioassay methodologies
C nom
HPLC Bioassay
C (lg/mL) Mean ± SD CV% RE% ± SD C (lg/mL) Mean ± SD CV% RE% ± SD
Within-day variability n = 6 Within-day variability n = 6
0.25 0.265 ± 0.005 1.99 6.08 ± 1.09 0.244 ± 0.012 5.06 )2.11 ± 4.96
0.5 0.537 ± 0.007 1.45 7.46 ± 0.59 0.539 ± 0.003 0.74 7.88 ± 0.80
1 1.000 ± 0.025 0.90 )3.05 ± 2.56 1.070 ± 0.031 2.90 7.03 ± 3.11
4 3.879 ± 0.023 0.61 )3.01 ± 1.56 4.12 ± 0.226 5.47 3.24 ± 5.65
8 7.722 ± 0.087 1.13 )3.46 ± 2.11 7.44 ± 0.208 2.80 )6.97 ± 2.60
Between-day variability n = 18 Between-day variability n = 12
0.25 0.250 ± 0.014 5.93 0.18 ± 2.57 0.248 ± 0.011 4.52 )0.41 ± 4.50
0.5 0.518 ± 0.015 2.99 3.70 ± 2.43 0.51 ± 0.035 6.82 2.65 ± 7.00
1 1.012 ± 0.021 2.11 1.26 ± 2.02 1.03 ± 0.084 8.14 3.77 ± 8.45
4 3.964 ± 0.102 2.59 )0.88 ± 2.43 3.90 ± 0.390 10.07 2.30 ± 9.84
8 7.801 ± 0.094 2.77 )2.48 ± 2.57 7.35 ± 0.432 5.88 )8.10 ± 5.41
CV% = standard deviation/mean of measured values ·100; RE% = [(mean measured concentration ) nominal concentration)/nominal concentration] ·100.
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behaviour) or the use of a simple mobile phase without buf-
fers or additives [11,13,20,21] make this a valuable method
for posaconazole quantification. However, such facilities might
not be available in all clinical microbiology laboratories
whereas bioassay facilities are almost certainly available. The
proposed bioassay has been shown to be a simple, inexpen-
sive and reliable method for posaconazole quantification. Our
data demonstrate sufficient accuracy and precision in spite of
the intrinsic variability described for this methodology (natural
antifungal serum activity [22,23] or the inhibition zones mea-
surement bias). However, it is worth noting that bioassay has
important limitations; first, bioassay quantifies the antifungal
activity, but fails to identify the drug or its active metabolites.
In addition, total inhibition zones can be modified by concomi-
tant antifungal drugs, and therefore they might not represent
correctly the serum antifungal concentration. In this study, we
found that results are comparable using these two different
methodologies (ICC value 0.915). Linear regression analysis
also shows a good correlation value between bioassay and
HPLC (coefficient of correlation = 0.931) and comparable
results (slope 0.742). Values in the HPLC are slightly greater,
probably because of the accuracy of the chromatographic
method compared with that of the bioassay, where an agar
diffusion procedure occurs before drug quantification.
Another point to consider is that although the lower limit
of quantification (0.125 lg/mL) of these two methods is rela-
tively high compared with that of the other reported meth-
ods such us ultra-performance liquid chromatography-UV or
liquid chromatography–tandem mass spectrometry
[13,15,21,24], the linearity range described here effectively
covers what is currently believed to be the clinically relevant
range for posaconazole concentrations in serum or plasma
(the Food and Drug Administration briefing document rec-
ommends a goal posaconazole average serum drug concen-
tration of 0.700 lg/mL; Andes et al. recommends
posaconazole trough values around 0.5 lg/mL for prophy-
laxis and between 0.5 and 1.5 lg/mL for therapy) [6,9].
Therefore it would not be a limitation with regard to their
usefulness in therapeutic drug monitoring.
Bioassay calibration curve
y = 5.1714Ln(x) + 22.607
R2 = 0.9987
0
5
10
15
20
25
30
35
40
0 2 4 6 8 10 12 14 16 18
Posaconazole concentration
D
ia
m
et
er
 (m
m
)
FIG. 1. Posaconazole bioassay linearity and calibration curve.
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FIG. 2. Scatter plot of posaconazole (PSZ) serum concentrations
(lg/mL) measured by HPLC and bioassay. Linear regression: Bioas-
say = 0.7425 (HPLC) + 0.026; R2 = 0.871, with a coefficient of cor-
relation = 0.931; n = 61 runs.
TABLE 3. Stability of posaconazole solutions after a variety
of storage and handling conditions
Peak area 1
posaconazole
average
Peak area 2
posaconazole
average
% posaconazole
average
Freeze–thaw stability
0.5 43 736 39 410 90.10
2 151 284 150 871 99.72
4 309 095 289 473 93.65
Short-term stability
0.5 43 736 38 439 87.88
2 151 284 145 499 96.17
4 309 095 303 908 98.32
Long-term stability
0.5 43 736 41 731 95.41
2 151 284 151 100 99.87
4 309 095 302 557 97.88
24 h 90 h 24 h 90 h
Post-preparative stability
0.5 43 736 34 767 27903 79.49 63.79
2 151 284 139 309 93987 92.08 62.12
4 309 095 300 142 177472 97.10 57.41
Stock solution stability
0.5 40 830 47 718 116.86
2 157 453 185 252 117.65
4 315 019 360 745 114.51
Peak area 1: Peak area detected at the beginning of the experiment. Peak area
2: peak area at the end of the experiment. % posaconazole average. For each
experimental condition posaconazole peak areas were compared with those
obtained at the beginning of the study and percentage of concordance was eval-
uated (maximum concordance 100%). Freeze–thaw stability (three freeze–thaw
cycles). Short-term storage (freeze for 24 h at )20C and then thaw for 4 h at
room temperature), long-term storage (freeze for 1 month at )20C and then
thaw for 4 h at room temperature); bench top stability (storage at room tem-
perature for 24 h and 90 h, and then processed), and stock solution stability
(evaluation of stock solution in dimethyl sulfoxide tested at the beginning of the
experiments and then after being stored at )20C for 2 months (estimated time
for this validation procedure).
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In summary, our study validates two methods for thera-
peutic drug monitoring of posaconazole and showed a good
concordance between the bioassay and HPLC for the mea-
surements of posaconazole serum levels in 61 samples. Both
methods have been validated for serum samples and not for
other body fluids. The HPLC method is more accurate,
more precise and faster, being more appropriate for thera-
peutic drug monitoring and pharmacokinetic studies. The
microbiological method, however, is relatively simple and
offers sufficient precision and accuracy to be used to moni-
tor drug levels in patients in routine clinical laboratories,
where chromatography equipment is not ordinarily available.
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